Affordable Access

deepdyve-link
Publisher Website

The latest treatment options for bladder cancer.

Authors
  • Crabb, Simon J1
  • Douglas, James2
  • 1 Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, Hampshire, UK.
  • 2 Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, UK.
Type
Published Article
Journal
British Medical Bulletin
Publisher
Oxford University Press
Publication Date
Dec 01, 2018
Volume
128
Issue
1
Pages
85–95
Identifiers
DOI: 10.1093/bmb/ldy034
PMID: 30371744
Source
Medline
Language
English
License
Unknown

Abstract

Bladder cancer carries a high healthcare burden and a poor prognosis once distant metastatic spread has occurred. We utilised a PubMed/MEDLINE literature search using the terms bladder cancer, chemotherapy, immunotherapy, intra-vesical therapy, surgery and radiotherapy, and current clinical management guidelines (Association of Cancer Physicians, British Association of Urological Surgeons, National Institute for Health and Care Excellence, European Association of Urology). Optimal bladder cancer management requires a multi-modal approach incorporating surgery, radiotherapy, chemotherapy and immunotherapy. Selection criteria for radical surgery, or radiotherapy as a bladder sparing option, and their relative efficacy, remains poorly defined. Palliative immunotherapy has been recently established for advanced bladder cancer after prior chemotherapy. Earlier use is under investigation. Validated predictive biomarkers, potentially from easily repeatable sites ('liquid biopsies'), will be required to optimise use of molecularly targeted treatment options.

Report this publication

Statistics

Seen <100 times